Cargando…

Development of potent antibody drug conjugates against ICAM1(+) cancer cells in preclinical models of cholangiocarcinoma

As a highly lethal adenocarcinoma of the hepatobiliary system, outcomes for cholangiocarcinoma (CCA) patients remain prominently poor with a 5-year survival of <10% due to the lack of effective treatment modalities. Targeted therapeutics for CCA are limited and surgical resection of CCA frequentl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Bing, Wang, Xinyan, Shimura, Takaya, Huang, Andrew C, Kong, Nana, Dai, Yujie, Fang, Jianmin, Guo, Peng, Ying, Jie-Er
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505223/ https://www.ncbi.nlm.nih.gov/pubmed/37717087 http://dx.doi.org/10.1038/s41698-023-00447-z

Ejemplares similares

ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma
por: Zhang, Peng, et al.
Publicado: (2023)

A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo
por: Guo, Peng, et al.
Publicado: (2023)

A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer
por: Huang, Jing, et al.
Publicado: (2020)

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
por: Zhang, Xinling, et al.
Publicado: (2022)

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
por: Kamath, Amrita V., et al.
Publicado: (2014)

Advances in preclinical evaluation of experimental antibody-drug conjugates
por: Lyons, Scott K., et al.
Publicado: (2021)

Antibody Conjugates Bispecific for Pollen Allergens and ICAM-1 with Potential to Prevent Epithelial Allergen Transmigration and Rhinovirus Infection
por: Weichwald, Christina, et al.
Publicado: (2023)

Potent Killing of Pseudomonas aeruginosa by an Antibody-Antibiotic Conjugate
por: Kajihara, Kimberly K., et al.
Publicado: (2021)

Targeting delivery of simvastatin using ICAM-1 antibody-conjugated nanostructured lipid carriers for acute lung injury therapy
por: Li, Shu-Juan, et al.
Publicado: (2017)

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
por: Donaghy, Heather
Publicado: (2016)

Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
por: Lucas, Andrew T., et al.
Publicado: (2019)

Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
por: Barreca, Marilia, et al.
Publicado: (2022)

RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models
por: Wong, Oi Kwan, et al.
Publicado: (2018)

HER2-Targeted Antibody–Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget’s Disease Models: In Vivo and Immunohistochemical Analyses
por: Tokuchi, Keiko, et al.
Publicado: (2022)

Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma
por: Lu, Xinjun, et al.
Publicado: (2023)

A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates
por: Xu, Ying, et al.
Publicado: (2017)

Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy
por: Vedvyas, Yogindra, et al.
Publicado: (2019)

Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors
por: Fan, Pengfei, et al.
Publicado: (2020)

Role of ICAM-1 in impaired retinal circulation in rhegmatogenous retinal detachment
por: Yokota, Harumasa, et al.
Publicado: (2021)

An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications
por: Pal, Lal Bahadur, et al.
Publicado: (2023)

Characterization of the function of intercellular adhesion molecule (ICAM)-3 and comparison with ICAM-1 and ICAM-2 in immune responses
Publicado: (1994)

Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate
por: Puthenveetil, Sujiet, et al.
Publicado: (2017)

The therapeutic effect of KSP inhibitors in preclinical models of cholangiocarcinoma
por: Shi, Yuanyuan, et al.
Publicado: (2022)

Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate
por: Sun, Zehua, et al.
Publicado: (2023)

Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer
por: Kanda, Mizuki, et al.
Publicado: (2022)

A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries
por: Klausz, Katja, et al.
Publicado: (2017)

Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates
por: Jackson, Dowdy, et al.
Publicado: (2014)

Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer
por: Bosco, Emily E., et al.
Publicado: (2018)

Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
por: Groothuis, Patrick G., et al.
Publicado: (2023)

Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
por: Bei, Yuncheng, et al.
Publicado: (2023)

SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
por: Mazahreh, Rebecca, et al.
Publicado: (2023)

Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer.
por: Burger, A. M., et al.
Publicado: (1996)

Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia
por: Leipold, Douglas D., et al.
Publicado: (2018)

Publisher Correction: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy
por: Vedvyas, Yogindra, et al.
Publicado: (2020)

ICAM-1 and ICAM-2 Are Differentially Expressed and Up-Regulated on Inflamed Pulmonary Epithelium, but Neither ICAM-2 nor LFA-1: ICAM-1 Are Required for Neutrophil Migration Into the Airways In Vivo
por: Chong, Deborah L. W., et al.
Publicado: (2021)

Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models
por: Kuo, Wei-Ying, et al.
Publicado: (2018)

Effective targeted therapy for drug-resistant infection by ICAM-1 antibody-conjugated TPGS modified β-Ga(2)O(3):Cr(3+) nanoparticles
por: Kang, Xu-Qi, et al.
Publicado: (2019)

POTENT AND SELECTIVE A2AR MONOCLONAL ANTIBODY ANTAGONIST FOR THE TREATMENT OF CANCER
por: Hu, Changyun, et al.
Publicado: (2023)

A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer
por: Hong, Xuwei, et al.
Publicado: (2023)

Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma
por: Krytska, Kateryna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e2nsmnffr7rdipt3ogsfsrsbcr